Andrea S. Kierans, Victoria Chernyak, Mishal Mendiratta‐Lala, Claude B. Sirlin, Elizabeth M. Hecht, Kathryn J. Fowler – 12 September 2022 – The Organ Procurement and Transplantation Network (OPTN) updated its allocation policy for liver transplantation to align with the Liver Imaging Reporting and Data System (LI‐RADS) for the diagnosis of hepatocellular carcinoma (HCC).

Francesco Vizzutti, Ciro Celsa, Salvatore Battaglia, Roberto Miraglia, Marco Enea, Fabio Marra, Antonio Colecchia, Calogero Cammà, Filippo Schepis – 12 September 2022

Samuel K. Handelman, Yindra M. Puentes, Annapurna Kuppa, Yanhua Chen, Xiaomeng Du, Mary F. Feitosa, Nicholette D. Palmer, Elizabeth K. Speliotes – 12 September 2022 – Nonalcoholic fatty liver disease (NAFLD) is prevalent worldwide. NAFLD is associated with elevated serum triglycerides (TG), low‐density lipoprotein cholesterol (LDL), and reduced high‐density lipoprotein cholesterol (HDL). Both NAFLD and blood lipid levels are genetically influenced and may share a common genetic etiology.

AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. 

Miran Kim, Kam Man Hui, Ming Shi, Nancy Reau, Costica Aloman – 11 September 2022 – Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) treatment to hepatocellular carcinoma (HCC) are effective tools to control tumor growth, prolong survival, palliate symptoms, and improve quality of life for patients with intermediate‐stage HCC.

Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley – 10 September 2022

Rebecca G. Kim, Janet N. Chu, Eric Vittinghoff, Jasmine Deng, Jewel N. Reaso, James P. Grenert, Mandana Khalili – 9 September 2022 – Fatty liver disease (FLD) is a leading cause of chronic liver disease (CLD) globally, and vulnerable populations are disproportionately affected. Prior studies have suggested racial/ethnic differences in FLD prevalence and severity; however, these studies often excluded Asian Americans.

Jin Ge, Jean C. Digitale, Mark J. Pletcher, Jennifer C. Lai, for the N3C Consortium – 9 September 2022

Cristina Rigamonti, Micol Giulia Cittone, Giulia Francesca Manfredi, Andrea Sorge, Riccardo Moia, Andrea Patriarca, Maria Francesca Donato, Gianluca Gaidano, Mario Pirisi, Mirella Fraquelli – 8 September 2022 – Spleen stiffness measurement (SSM) by vibration‐controlled transient elastography (VCTE) is a noninvasive technique for estimating portal hypertension in patients with chronic liver disease (CLD), with its reproducibility yet to be established and its feasibility still unknown beyond CLD.

Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida – 8 September 2022 – Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a consequence of failed early detection. Professional societies recommend semi‐annual HCC screening in at‐risk patients with chronic liver disease to increase the likelihood of curative treatment receipt and improve survival.